"Laboratory medicine: Preparing for the 2020's"



BUDAPEST NOVEMBER 9-11, 2018

# Standardization of HbA<sub>2</sub>: a long way to succeed

Andrea Mosca

Centro per la Riferibilità metrologica in Medicina di Laboratorio Dip. Fisiopatologia medico-chirurgica e dei trapianti Università degli Studi di Milano

- \* Why HbA<sub>2</sub> is important
- \* State of the art
- \* Activities of the IFCC WG-HbA<sub>2</sub>
- \* Reducing inter-laboratory variability

2

\* Future perspectives



### \* Why HbA<sub>2</sub> is important

- \* Stat
- \* Autivities of the IFCC WG-HbA
- \* Roducing inter-laboratory variability
- \* Future perspectives

# \*contents

A. Mosca - UniMI



### World Distribution, Population Genetics, and Health Burden of the Hemoglobinopathies

#### Thomas N. Williams<sup>1</sup> and David J. Weatherall<sup>2</sup>

3

<sup>1</sup>Kenya Medical Research Institute/Wellcome Trust Programme, Centre for Geographical Research, Killii Digrict Hospital, PO Box 230, Killili, Kenya

<sup>3</sup>Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX39DU, United Kingdom

Correspondence: twilliams@kilifi.lamri-wellcome.org

| Table 1. | A breakdown of the annual number of hirths |
|----------|--|
| with the | different herooglabin disorders            |

| Annual births with major hemoglol                   | bin disorders |
|---|---------------|
| β-thalassemia major                                 | 22,989        |
| HbE B thalassemia                                   | 19,128        |
| HbH disease   | 9568          |
| Hb Bart's hydrops (a <sup>0</sup> /a <sup>0</sup> ) | 5183          |
| SS discuse  | 217,331       |
| S β thalassemia                                     | 11.074        |
| SC disease  | 54,736        |

From available data (Modell and Darlison 2006; Weatherell 2010).



## The role of haemoglobin $A_2$ testing in the diagnosis of thalassaemias and related haemoglobinopathies

A Mosca,<sup>1</sup> R Paleari,<sup>1</sup> G Ivaldi,<sup>2</sup> R Galanello,<sup>3</sup> P C Giordano<sup>4</sup>











9

Paleari et al, Clin Chim Acta 2018;477:60-5



Fig. Lines-laboratories results obtained from two different RQMs previous, at three different leavis of RMs, total hemselphila amount of substance tractices, prosped according to the methods used by the participants. The inferent RQMs previous distances in 2018 from the Tallan hers-degrad. Program: The right parel refers to the data obtained from two the intermediated by the participants. The inferent reports the data obtained to 2018 from the Tallan hers-degrad. Program: The right parel refers to the data obtained from two the intermediated by provided by the 2-dat obtainations. The authories in participants pare method are reported in Instalnet, from the lower to the higher RMs, level. Point and one has represent means and 50, respectively. The dotted later reported the linear of the allocable total error of ± TK.

Paleari et al, Clin Chima Acta 2017;467:21-6





### 1. Definition of a reference measurement procedure using mass spectrometry associated with proteolytic degradation

A. Mosca - UniMI

13

| Approved IFCC Reference Method fo<br>of HbA <sub>1c</sub> in Human Blood  | IFCC 2002/1.  |
|---|---|
| nternational Federation of Clinical Chemistry and<br>Laboratory Medicine (IFCC) <sup>1221</sup><br>Scientific Division<br>Working Group on HbA <sub>16</sub> , Standardisation <sup>20</sup> and<br>Vetwork of Reference Laboratories for HbA <sub>16</sub> <sup>4</sup><br>Prepared for publication <sup>50,69</sup> by<br>Nan-Olof Jeppsson <sup>1,7</sup> , Uwe Kobold <sup>9</sup> , John Barr <sup>3</sup> , Andreas<br>Tinke <sup>9</sup> , Wuleand Hoelze <sup>9</sup> , Tatao Hoshino <sup>6</sup> , Kor Miedema <sup>3</sup> ,<br>Andrea Mose <sup>20</sup> , Pierluigi Mauri, Rite Paron <sup>1</sup> , Linda<br>Thienpont <sup>9</sup> , Masao Umemoto <sup>19</sup> and Cas Weykamp <sup>11</sup> | Image: start   Mill Complete:   Mill Com |

2005 -2009 activities

#### Development of the methods

> Choise of the proteolitic enzyme (endoproteinase Lys C, Trypsin)

Definition of digestion protocol (denaturation step with acetonitrile, trifluoroethanol, rapigest, digestion time, temperature, time course)

- > Choise of marker peptides ( $\delta T2$ ,  $\delta T3$ ,  $\delta T14$ ,  $\alpha T4$ ,  $\alpha T5$ ,  $\alpha T11$ )
- > Choise of column (Tosoh TSK gel, Zorbax)
- > Analytical condition
- > ESI-MS detection (double-charge, mono-charge)

A. Mosca - UniMI

15

2005 -2009 activities

#### Interlaboratory exercizes

- 2006: 6 calibrators, 29 samples
- 2007: 6 calibrators, 20 samples (2 digestions, 2 replicates/digested)
- 2008: 4 calibrators, 3 samples (3 digestions, 3 replicates/digested)
- 2009: 1 calibrators, 1 samples (centralized digestion, measurements over 5 days)

> Inter-laboratory variability







## Repeatability and within-lab precision of HbA2 determination using IDMS (EP15-A3)

| Table 2       | repeatabili  | ty and withir | -lab precisio        | nofHbA₂de | termination | usingIDMS |
|---------------|--------------|---------------|----------------------|-----------|-------------|-----------|
|               | day          | aliquot 1     | aliquot 2            | aliquot 3 | mean        | SD        |
|               |              |               | HbA <sub>2</sub> (%) |           |             | (%)       |
|               | 1            | 2.95          | 3.00                 | 2.91      | 2.95        | 1.53      |
|               | 2            | 2.96          | 2.95                 | 3.01      | 2.97        | 1.08      |
| sample 1      | 3            | 2.94          | 2.91                 | 3.02      | 2.96        | 1.92      |
|               | 4            | 2.99          | 2.99                 | 3.07      | 3.02        | 1.53      |
|               | 5            | 3.03          | 2.97                 | 3.06      | 3.02        | 1.52      |
| repeatability | (%)          | 1.50          |                      |           |             |           |
| within-lab p  | recision (%) | 1.68          |                      |           |             |           |

Arsene et al, Clinica Chimica Acta 2018



![](_page_10_Figure_2.jpeg)

![](_page_11_Figure_1.jpeg)

Development of a candidate certified refernce material (CRM)

- Lyophilized material

![](_page_11_Figure_4.jpeg)

![](_page_12_Figure_1.jpeg)

## Stability of the lyophilized material

![](_page_12_Figure_3.jpeg)

![](_page_13_Figure_1.jpeg)

|           |                                     |           |            |            |     |             |           |            |               |               |   |            | Clinic       | a Chir     | nica A      | Acta 4      | 77 (2)    | 018) 60     | 0–65         |            |           |      |     |      |    |    |     |
|-----------|-------------------------------------|-----------|------------|------------|-----|-------------|-----------|------------|---------------|---------------|---|------------|--------------|------------|-------------|-------------|-----------|-------------|--------------|------------|-----------|------|-----|------|----|----|-----|
| -         | ġ,                                  |           |            |            |     |             |           |            |               |               | Contents lists available at ScienceDirect |            |              |            |             |             |           |             |              |            |           |      |     |      |    |    |     |
| AL YES    | Clinica<br>JOURNE JOURNAL HOMEPAGE: |           |            |            |     |             |           |            |               |               |   | 1 C.       | Chimica Acta |            |             |             |           |             |              |            |           |      |     |      |    |    |     |
| Ca<br>dif | li∣<br>ff€                          | br<br>ere | ati<br>enc | ior<br>ces | ı b | y c<br>f ci | om<br>1rr | imi<br>ent | utal<br>: hiş | ole c<br>gh-p | on<br>erf                                 | tro<br>orr | l n<br>nai   | nat<br>nce | eria<br>e m | als<br>ietl | is<br>100 | abl<br>ls f | e to<br>or F | re<br>Ib/  | du<br>4₂≉ | ce i | int | er-: | me | th | od  |
| w         | who                                 |           |            |            |     |             | Ly        | oho        | che           | k 1           |   |            |              |            | Ly          | Lyphochek 2 |           |             |              |            |           |      |     |      |    |    |     |
|           | T                                   | 1         | 2          | 3          | 4   | 5           | 6         | 7          | 8             |               | 1   | 2          | 3            | 4          | 5           | 6           | 7         | 8           |              | 1          | 2         | 3    | 4   | 5    | 6  | 7  | 8   |
| 1         | t                                   |           | -          |            |     | 1           | Ľ         |            |               | 1             |   |            |              |            |             |             |           |             | 1            |            |           |      |     |      | -  |    |     |
| 2         |                                     | 1         |            |            |     |             |           |            |               | 2             | $\checkmark$                              | 12         |              |            |             |             |           |             | 2            |            | 101       | -    |     |      |    |    |     |
| 3         |                                     |           |            | 1917       |     |             |           |            |               | 3             | 4   | 4          |              |            |             |             |           |             | 3            | ٠          | ٠         |      |     |      |    |    |     |
| 4         |                                     |           | ٠          | 4          |     |             |           |            |               | 4             | X   | 1          | V            |            |             |             |           |             | 4            |            | V         | ٠    |     |      |    |    |     |
| 5         | Ŀ                                   | 4         | 1          | ×          | ×.  |             |           |            |               | 5             | 1   | 4          | V            | v          |             |             | _         |             | 5            | 1          | 4         | ٠    |     |      |    |    |     |
| 6         | 4                                   | 4         | <          | ٠          | •   | ¥           |           | _          |               | 6             | 4   | 4          | Y.           | V          | ×           |             | _         |             | 6            | 1          | 4         | ٠    | ٠   | 1    |    |    | _   |
| 7         | Ŀ                                   | •         | •          | 1          | 4   | 1           | •         | 100        |               | 7             | ×   | V          | 1            | V.         | 4           | 4           | 201       |             | 7            | 4          | ٠         | ٠    | ٠   | 4    | ×. |    | 1   |
| 8         | 1.                                  |           | •          | ٠          | •   | •           | 1         | •          |               | 8             | 1.4                                       | ×          | ×            | Y          | ¥           | ¥.          | Ý         | 115         | 8            | ٠          | •         | •    | ٠   | ¥    | ٠  |    | 100 |
| RF        | ' 1                                 |           |            |            |     |             |           |            |               | RP            | 2   |            |              |            |             |             |           |             | RF           | <b>,</b> 3 |           |      |     |      |    |    |     |
|           | Г                                   | 1         | 2          | 3          | 4   | 5           | 6         | 7          | 8             |               | 1   | 2          | 3            | 4          | 5           | 6           | 7         | 8           | T.           | 1          | 2         | 3    | 4   | 5    | 6  | 7  | 8   |
| 1         | B                                   |           |            |            |     |             |           |            |               | 1             |   |            |              |            |             |             |           |             | 1            | 10         |           |      |     |      |    |    |     |
| 2         |                                     | 1         |            |            |     |             |           |            |               | 2             | ¥.  |            |              |            |             |             |           |             | 2            | V          | 100       |      |     |      |    |    |     |
| 3         | Ŀ                                   | 4         | ×          | 111        |     |             |           |            |               | 3             | 4   | 1          |              |            |             |             |           |             | 3            | X          | 1         |      |     |      |    |    |     |
| 4         |                                     | 1         | 1          | V          |     |             |           |            |               | 4             | 4   |            |              |            |             |             |           |             | 4            | 4          | 4         | Y    |     |      |    |    |     |
| 5         | Ŀ                                   | 4         | 1          | 4          | 14  | 122         |           |            |               | 5             | 1   | 1          | 1            | 1          | 1           | _           | _         |             | 5            | 4          | 4         | 4    | 1   | 13   |    |    |     |
| 6         | ŀ                                   | 4         | 1          | 1          | ×.  | 1           |           | _          |               | 6             |   |            |              | V          | ×,          | 10.00       | -         |             | 6            |            | V         |      | 1   | 1    |    |    | -   |
| 7         |                                     | 4         | √.         | 1          | V.  | 4           | ¥         | 112        |               | 7             | V   | Y          |              | ٠          | ×,          | ٠           |           |             | 7            | V          | 1         | V    | 4   | V    |    |    | 1   |
| . 8       | I.v                                 | 1         | 4          | 1          | sv  | 14          | V.        | V          |               | 8             | V.  | 1          | V.           |            |             |             | v         |             | 8            | 11         | 14        | 15   | 12  | 81   | 1. | 12 | 100 |

14

![](_page_14_Figure_1.jpeg)

![](_page_14_Picture_2.jpeg)

![](_page_15_Figure_1.jpeg)

- \* IFCC WG members (R. Paleari, C, Arsene, P, Kaiser)
- \* C. Hartefeld (Leiden University, NL)
- \* I. Zegers, H. Schimmel (JRC, BE)

# \*acknowledgements